Literature DB >> 32833260

Outcomes in N3 Head and Neck Squamous Cell Carcinoma and Role of Upfront Neck Dissection.

Angela Boros1, Pierre Blanchard1,2, Arlette Dade3, Philippe Gorphe3, Ingrid Breuskin3, Caroline Even3, France Nguyen1, Eric Deutsch1,2,4, François Bidault5, François Janot3, Stephane Temam3, Haitham Mirghani3, Yungan Tao1,2,4.   

Abstract

OBJECTIVES: We investigated the prognostic factor of N3 head and neck squamous cell carcinoma (HNSCC), including the role of upfront neck dissection (UFND) before radiotherapy (RT).
METHODS: We retrospectively reviewed the charts of consecutive N3 HNSCC patients treated with curative intent RT.
RESULTS: In the study, 323 N3 HNSCC patients were included. Of those, 125 patients (39%) had UFND. Median follow-up was 3.9 years (0-14.8 years). Overall survival (OS) at 5 years was 31.2%, and progression-free survival (PFS) was 26%. In the multivariate analysis, OS was improved in PS 0, T1-2 tumors, patients receiving concurrent chemotherapy, never or former smokers, and UFND. UFND was strongly associated with increased OS (45.7% vs. 21.2%, P < .001), and PFS (P < .001). Regardless of neck node size, UFND improved survival (P = .001 for ≤ 7 cm and P = .004 for > 7 cm).
CONCLUSION: UFND could improve treatment outcomes in N3 HNSCC, especially for non-oropharyngeal cancer, regardless of neck node size. LEVEL OF EVIDENCE: 2B Laryngoscope, 131:E844-E850, 2021.
© 2020 The American Laryngological, Rhinological and Otological Society, Inc.

Entities:  

Keywords:  Head and neck cancer; N3; chemoradiotherapy; neck dissection

Mesh:

Year:  2020        PMID: 32833260     DOI: 10.1002/lary.28893

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  1 in total

1.  Impact of Neck Dissection in Head and Neck Squamous Cell Carcinomas of Unknown Primary.

Authors:  Yazan Abu-Shama; Julia Salleron; Florent Carsuzaa; Xu-Shan Sun; Carole Pflumio; Idriss Troussier; Claire Petit; Matthieu Caubet; Arnaud Beddok; Valentin Calugaru; Stephanie Servagi-Vernat; Joël Castelli; Jessica Miroir; Marco Krengli; Paul Giraud; Edouard Romano; Jonathan Khalifa; Mélanie Doré; Nicolas Blanchard; Alexandre Coutte; Charles Dupin; Shakeel Sumodhee; Yungan Tao; Vincent Roth; Lionel Geoffrois; Bruno Toussaint; Duc Trung Nguyen; Jean-Christophe Faivre; Juliette Thariat
Journal:  Cancers (Basel)       Date:  2021-05-17       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.